BOSTON, June 22,
2023 /PRNewswire/ -- Haemonetics Corporation (NYSE:
HAE), a global medical technology company focused on delivering
innovative solutions to drive better patient outcomes, today
announced it has received clearance from the U.S. Food and Drug
Administration (FDA) for advancements to its NexSys PCS® plasma
collection system. These include a new plasma collection bowl,
featuring a patented design that optimizes performance, and new
Express® Plus Technology engineered to reduce procedure time.
Haemonetics is the leader in the plasma collections market, with
five decades of industry experience and over 50 million real-world
collections to date on NexSys PCS, the industry's most advanced,
completely integrated system designed to streamline plasma
collections and improve yield, productivity, safety, quality,
compliance and donor satisfaction. With the latest advancements,
Haemonetics expects an average procedure time of 33 to 38 minutes
using the standard FDA nomogram, helping customers achieve new
levels of plasma center efficiency and lower costs to
collect.
The bi-directionally connected NexSys PCS with NexLynk DMS®
donor management software already delivers a 16-minute reduction in
donor door-to-door time, on average, with a significant portion of
this improvement occurring pre- and post-procedure. Additionally,
NexSys PCS with Persona® Technology safely delivers on average a
+9% to 12% additional plasma yield by personalizing each collection
to the individual donor characteristics. Haemonetics is planning an
initial market release of NexSys PCS with the new bowl and Express
Plus Technology over the coming months.
"Haemonetics sets the standard in global plasma collection
solutions that meet collectors' most critical needs. With our
redesigned bowl and new Express Plus Technology for faster
procedure times and enhanced plasma center efficiency, we continue
to advance our innovation to lead the industry in reducing cost per
liter for collectors and ensuring the best experience for their
donors," said Roy Galvin,
President, Global Plasma and Blood Center at Haemonetics.
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company
dedicated to providing a suite of innovative medical products and
solutions for customers, to help them improve patient care and
reduce the cost of healthcare. Our technology addresses important
medical markets: blood and plasma component collection, the
surgical suite and hospital transfusion services. To learn more
about Haemonetics, visit www.haemonetics.com.
Cautionary Statement Regarding Forward-Looking
Information
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Forward-looking statements in this press release may
include, without limitation, statements regarding plans and
objectives of management for the operation of Haemonetics,
including statements regarding potential benefits associated with
the redesigned plasma collection bowl and new Express Plus
Technology for the NexSys PCS plasma collection system, and
Haemonetics' plans or objectives related to the commercialization
of these product enhancements. Such forward-looking statements are
not meant to predict or guarantee actual results, performance,
events or circumstances and may not be realized because they are
based upon Haemonetics' current projections, plans, objectives,
beliefs, expectations, estimates and assumptions and are subject to
a number of risks and uncertainties and other influences.
Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, product quality and performance;
market acceptance; the effect of economic and political conditions;
the impact of inflationary pressures in our global manufacturing
and supply chain; the impact of competitive products and pricing;
blood product reimbursement policies and practices; and the effect
of industry consolidation as seen in the plasma market. These and
other factors are identified and described in more detail
in Haemonetics' periodic reports and other filings with the
U.S. Securities and Exchange Commission. Haemonetics does not
undertake to update these forward-looking statements.
Investor
Contacts:
|
|
Olga Guyette, Sr.
Director-Investor Relations & Treasury
|
David
Trenk, Manager-Investor Relations
|
(781) 356-9763
|
(203)
733-4987
|
olga.guyette@haemonetics.com
|
david.trenk@haemonetics.com
|
|
Media
Contact:
|
Josh Gitelson,
Director-Global Communications
|
(781)
356-9776
|
josh.gitelson@haemonetics.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/haemonetics-receives-fda-clearance-for-enhancements-to-nexsys-pcs-plasma-collection-system-301857879.html
SOURCE Haemonetics Corporation